FDA Panel Split On DURECT's Drug, Intellipharma Plunges, BNTX To Acquire NTGN

Today's Daily Dose brings you news about the FDA panel's split verdict on DURECT's postoperative nonopioid pain relief depot, BioNTech's acquisition of Neon Therapeutics and the FDA designating Envafolimab as an orphan drug for the treatment of biliary tract cancer.

from RTT - Biotech https://ift.tt/30sINEc
via IFTTT